SNSE Sensei Biotherapeutics

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will participate in the New Radiotherapy and Targeted Therapy Approaches panel at the Canaccord Genuity Horizons in Oncology Virtual Conference on Monday, April 7 at 2:00 p.m. ET.

About Sensei Biotherapeutics 

Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead product candidate is solnerstotug, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. For more information, please visit , and follow the company on X @SenseiBio and .

Investor Contact:

Michael Biega

Senior Director, Investor Relations

Sensei Biotherapeutics

Media Contact:

Joyce Allaire

LifeSci Advisors



EN
02/04/2025

Underlying

SNSESensei Biotherapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sensei Biotherapeutics

 PRESS RELEASE
Free
SNSE Sensei Biothera...

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizon...

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will participate in the New Radiotherapy and Targeted Therapy Approaches panel at the Canaccord Genuity Horizons in Oncology Virtual Conference on Monday, April 7 at 2:00 p.m. ET. About Sensei Biot...

April 2, 2025 1 EN
 PRESS RELEASE
Free
SNSE Sensei Biothera...

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Up...

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress - Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant “hot” tumor patient population - - Solnerstotug continues to demonstrate a well-tolerated safety and tolerability profile - - Achieved target enrollment in dose expansion cohort; full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: S...

March 28, 2025 1 EN
 PRESS RELEASE
Free
SNSE Sensei Biothera...

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Da...

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors – Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response rates, with data still maturing – – One durable complete response in a Merkel Cell Carcinoma (MCC) patient and two partial responses (PR), including one in a second MCC patient and one in a microsatellite instability-high (MSI-H) Colorectal Cancer (CRC) patient, all of whom were previously treated with and progressed on immunother...

March 27, 2025 1 EN
 PRESS RELEASE
Free
SNSE Sensei Biothera...

Sensei Biotherapeutics to Participate in Oppenheimer’s 35th Annual Hea...

Sensei Biotherapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference BOSTON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference, being held virtually, on Tuesday, February 11, 2025 at 10:40 a.m. ET.   A webcast of Sensei’s presentation will be avai...

February 4, 2025 1 EN
 PRESS RELEASE
Free
SNSE Sensei Biothera...

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Up...

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones - Solnerstotug (SNS-101) dose expansion arm anticipated to be fully enrolled by end of Q1 2025 - - Clinical data update expected in Q2 2025 - BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today provided corporate updates on its lead program, solnerstotug (SNS-101) and upcoming milestones. “2024 was a noteworthy year for Sensei ...

January 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch